Targeting the SH2 Domain-Containing Inositol Phosphatase (SHIP) for Therapy
Authors: Mehta, Payal; Butchar, Jonathan P.; Tridandapani, Susheela
Source: Current Enzyme Inhibition, Volume 5, Number 3, October 2009 , pp. 153-162(10)
Publisher: Bentham Science Publishers
Abstract:SHIP (SH2 domain containing inositol phosphatases) was identified as a 145kDa multi-domain cytosolic protein expressed specifically in hematopoietic cells that negatively regulates cell growth, survival and proliferation. Aberrant SHIP function is associated with many disease pathologies. There are two aspects to SHIP function: the catalytic function mediated by the central catalytic domain and the non-catalytic function mediated by the protein-protein interaction domains of SHIP. Much is known about the catalytic function of SHIP and its role in regulation of growth factor and immune receptor signaling. However, not much is known about the mechanistic details of the non-catalytic functions of SHIP and this is an active area of research. In this review, we discuss the role of SHIP in different cell types of immune system, its role in various diseases and its potential as a therapeutic target.
Document Type: Research Article
Publication date: October 1, 2009
- Current Enzyme Inhibition aims to publish all the latest and outstanding developments in enzyme inhibition studies with regards to the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of enzymes that can be exploited for drug development. Current Enzyme Inhibition is an essential journal for every pharmaceutical and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.